Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20723484 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30890373 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL20723487 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL1070057 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30076247 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL8616589 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL17696519 | 1.00 | GSR (0.60) | GSRFOLH1DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL4328805 | 0.98 | GSR (0.58) | GSRFOLH1DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL10439913 | 0.98 | GSR (0.58) | GSRFOLH1DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL1419587 | 0.98 | GSR (0.58) | GSRFOLH1DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (US) | 2026-04-16 | — | — | US | claimed |
| US-20250009850-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HUMAN HYALURONIDASE PH20 AND DRUG | ALTEOGEN, INC. (KR) | 2025-01-09 | — | — | US | claimed |
| CN-119015834-A | Carbon dioxide separation membrane and preparation method thereof | 国家能源投资集团有限责任公司 | 2024-11-26 | — | — | CN | claimed |
| US-12116424-B2 | Compounds and compositions for modulating Listeria virulence | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-10-15 | — | — | US | claimed |
| CN-118695873-A | Pharmaceutical composition comprising human hyaluronidase PH20 and a drug | 阿特根公司 | 2024-09-24 | — | — | CN | claimed |
| EP-4424301-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HUMAN HYALURONIDASE PH20 AND DRUG | Alteogen, Inc. (KR) | 2024-09-04 | — | — | EP | claimed |
| WO-2024104138-A1 | N-TERMINAL FUNCTIONALIZATION-MODIFIED CYSTYL DIOLEYLAMINE COMPOUND, CHEMICAL SYNTHESIS METHOD THEREFOR, AND USE THEREOF | 北京大学 | 2024-05-23 | — | — | WO | claimed |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2024-05-09 | — | — | US | claimed |
| WO-2024058648-A1 | NOVEL HYALURONIDASE PH-20 VARIANT, AND USE THEREOF | (주)피앤피바이오팜 | 2024-03-21 | — | — | WO | claimed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | claimed |
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | claimed |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-10 | — | — | US | claimed |
| WO-2012174478-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2012-12-20 | — | — | WO | claimed |
| US-5856308-A | POLYPEPTIDES; WOUND HEALING AGENTS | HAEMACURE CORPORATION (CA) | 1999-01-05 | — | — | US | claimed |
| EP-0182356-B2 | Nutrient compositions | MONTEFIORE HOSPITAL ASS OF WES (US) | 1998-08-05 | — | — | EP | claimed |
| EP-0462669-B1 | Amine enriched proteins | JOHNSON & JOHNSON CLIN DIAG (US) | 1996-11-13 | — | — | EP | claimed |
| US-5162219-A | Reacting with amide bond forming agent in presence of polyamine; labels in immunoassay | EASTMAN KODAK COMPANY (US) | 1992-11-10 | — | — | US | claimed |
| EP-0462669-A2 | Amine enriched proteins | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | claimed |
| US-5034377-A | Dipeptides and tripeptides for use as nutrients in diets | MONTEFIORE HOSPITAL ASSOCIATION OF WESTERN PENNSYLVANIA (US) | 1991-07-23 | — | — | US | claimed |
| EP-0182356-A2 | Nutrient compositions | The Montefiore Hospital Association of Western Pennsylvania (US) | 1986-05-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | IDE, MMP20, IDUA | GSR 4631/4885FOLH1 97/4885DPP8 183/4885 |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | GSR 684/4885FOLH1 221/4885DPP8 1691/4885 |
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | CBR1, CBR3, SIGMAR1 | GSR 143/4885FOLH1 1156/4885DPP8 1462/4885 |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | IDE, IDUA, MMP20 | GSR 4741/4885FOLH1 120/4885DPP8 183/4885 |
| US-12116424-B2 | Compounds and compositions for modulating Listeria virulence | LTN1, LOXL1, LTA | GSR 4466/4885FOLH1 4186/4885DPP8 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.